<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17283721</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ardura, Manuel Alvarez</dc:author>
<dc:author>Llorente, Carlos</dc:author>
<dc:author>de la Morena, José Manuel</dc:author>
<dc:description xml:lang="en">OBJECTIVES To review the value of PSA kinetics in the diagnosis and prognosis of prostate cancer. METHODS Review of the literature through a Medline search. CONCLUSIONS A pre-tretament PSAV value &gt;2ng/ ml/yr is a risk factor for increased mortality from prostate cancer after surgery or radiation therapy. A PSADT&lt;3ms is indicative of reduced survival after treatment. For patients with PSA recurrence after surgery a PSADT&gt; 10 is more likely associated with local recurrence.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2006 Dec </dc:date>
<dc:title xml:lang="es">El tiempo de doblaje de PSA como nuevo método diagnóstico y pronóstico del cáncer de próstata.</dc:title>
<dc:title xml:lang="en">[PSA doubling time as a new diagnostic and prognostic method for prostate cancer].</dc:title>
<dc:publisher>Archivos espanoles de urologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
